妊娠早期诊断的妊娠期糖尿病的治疗
该研究为随机对照试验,纳入妊娠4周至19周6天、具有高血糖危险因素且符合世界卫生组织2013标准诊断妊娠期糖尿病的女性802例(立即治疗组406例,对照组396例)。对照组根据妊娠24至28周重复口服葡萄糖耐量试验结果决定延迟治疗或不治疗。立即治疗组不良新生儿结局复合终点发生率为24.9%(94/378),对照组为30.5%(113/370),校正风险差-5.6个百分点(95%CI -10.1至-1.2)。妊娠相关高血压(10.6% vs 9.9%,校正风险差0.7个百分点,95%CI -1.6至2.9)和新生儿瘦体重(2.86 kg vs 2.91 kg,校正均数差-0.04 kg,95%CI -0.09至0.02)无实质差异。
要点
- 妊娠20周前诊断的妊娠期糖尿病立即治疗,不良新生儿结局复合终点24.9%(94/378) vs 30.5%(113/370),校正风险差-5.6个百分点(95%CI -10.1至-1.2)。
- 妊娠相关高血压立即治疗组10.6%(40/378) vs 对照组9.9%(37/372),校正风险差0.7个百分点(95%CI -1.6至2.9),无实质差异。
- 新生儿瘦体重立即治疗组2.86 kg vs 对照组2.91 kg,校正均数差-0.04 kg(95%CI -0.09至0.02),无实质差异。
- 筛查和治疗相关的严重不良事件未观察到组间差异。
- 初次口服葡萄糖耐量试验在平均15.6±2.5周妊娠时进行。
适用人群与场景
- 妊娠4周至19周6天、具有高血糖危险因素且符合世界卫生组织2013标准诊断妊娠期糖尿病的女性。
诊断标准与关键阈值
- 妊娠期糖尿病诊断采用世界卫生组织2013标准。
- 对照组在妊娠24至28周进行重复口服葡萄糖耐量试验,根据结果决定延迟治疗或不治疗。
处置流程与药物剂量
- 立即治疗组:诊断后立即接受妊娠期糖尿病治疗。
- 对照组:根据妊娠24至28周重复口服葡萄糖耐量试验结果决定延迟治疗或不治疗。
研究设计与关键结果
- 随机对照试验,802例女性按1:1随机分配至立即治疗组(406例)或对照组(396例),793例(98.9%)有随访数据。
- 初次口服葡萄糖耐量试验在平均15.6±2.5周妊娠时进行。
- 不良新生儿结局复合终点(妊娠<37周分娩、产伤、出生体重≥4500 g、呼吸窘迫、光疗、死产或新生儿死亡、肩难产):立即治疗组94/378(24.9%) vs 对照组113/370(30.5%),校正风险差-5.6个百分点(95%CI -10.1至-1.2)。
- 妊娠相关高血压(子痫前期、子痫或妊娠期高血压):立即治疗组40/378(10.6%) vs 对照组37/372(9.9%),校正风险差0.7个百分点(95%CI -1.6至2.9)。
- 新生儿瘦体重:立即治疗组2.86 kg vs 对照组2.91 kg,校正均数差-0.04 kg(95%CI -0.09至0.02)。
- 筛查和治疗相关的严重不良事件未观察到组间差异。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对妊娠20周前诊断的妊娠期糖尿病,立即治疗可使不良新生儿结局复合终点小幅降低;对妊娠相关高血压和新生儿瘦体重无实质影响。
- 筛查和治疗相关的严重不良事件未观察到组间差异。
指南或共识出处
- TOBOGM试验,澳大利亚新西兰临床试验注册号ACTRN12616000924459;由National Health and Medical Research Council等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether treatment of gestational diabetes before 20 weeks' gestation improves maternal and infant health is unclear.
METHODS: We randomly assigned, in a 1:1 ratio, women between 4 weeks' and 19 weeks 6 days' gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria) to receive immediate treatment for gestational diabetes or deferred or no treatment, depending on the results of a repeat oral glucose-tolerance test [OGTT] at 24 to 28 weeks' gestation (control). The trial included three primary outcomes: a composite of adverse neonatal outcomes (birth at <37 weeks' gestation, birth trauma, birth weight of ≥4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder dystocia), pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension), and neonatal lean body mass.
RESULTS: A total of 802 women underwent randomization; 406 were assigned to the immediate-treatment group and 396 to the control group; follow-up data were available for 793 women (98.9%). An initial OGTT was performed at a mean (±SD) gestation of 15.6±2.5 weeks. An adverse neonatal outcome event occurred in 94 of 378 women (24.9%) in the immediate-treatment group and in 113 of 370 women (30.5%) in the control group (adjusted risk difference, -5.6 percentage points; 95% confidence interval [CI], -10.1 to -1.2). Pregnancy-related hypertension occurred in 40 of 378 women (10.6%) in the immediate-treatment group and in 37 of 372 women (9.9%) in the control group (adjusted risk difference, 0.7 percentage points; 95% CI, -1.6 to 2.9). The mean neonatal lean body mass was 2.86 kg in the immediate-treatment group and 2.91 kg in the control group (adjusted mean difference, -0.04 kg; 95% CI, -0.09 to 0.02). No between-group differences were observed with respect to serious adverse events associated with screening and treatment.
CONCLUSIONS: Immediate treatment of gestational diabetes before 20 weeks' gestation led to a modestly lower incidence of a composite of adverse neonatal outcomes than no immediate treatment; no material differences were observed for pregnancy-related hypertension or neonatal lean body mass. (Funded by the National Health and Medical Research Council and others; TOBOGM Australian New Zealand Clinical Trials Registry number, ACTRN12616000924459.).
参考来源
- Simmons D, Immanuel J, Hague WM, et al. Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. N Engl J Med. 2023. PMID: 37144983. doi:10.1056/NEJMoa2214956
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。